RxDoctor Payments Data

Timothy Nickel, MD

Allergy · Tulsa, OKNPI 1154302354

Payments from drug & device makers

$51,455in general payments, 2019–2025

Across 441 payments — averaging $116.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharming Healthcare, Inc.$20K
  • Genentech USA, Inc.$16K
  • Shire North American Group Inc$4K
  • Biocryst Pharmaceuticals, Inc.$3K
  • AstraZeneca$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$11,95323%
  • Speaking & faculty fees$23,75046%
  • Travel & lodging$6,08512%
  • Food & beverage$9,36618%
  • Education$3011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$721,538
Medicare patients
715
Services billed
25,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo33$1,703,152
IcatibantIcatibant Acetate12$408,448
Dupixent PenDupilumab31$120,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$84,491
XolairOmalizumab25$68,162
Dupixent SyringeDupilumab13$47,583
Breo ElliptaFluticasone/Vilanterol87$36,160
Epinephrine114$20,570
Spiriva RespimatTiotropium Bromide23$13,021
SymbicortBudesonide/Formoterol Fumarate35$9,408
Arnuity ElliptaFluticasone Furoate23$8,126
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$5,249
Montelukast Sodium256$4,542
Qvar RedihalerBeclomethasone Dipropionate13$4,434
Advair HfaFluticasone Propion/Salmeterol14$4,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$1,237$1,703,15233 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$753$128,778208 claims
Genentech, Inc.Xolair$144$68,16225 claims
Boehringer IngelheimSpiriva Respimat$20$13,02123 claims
AstraZenecaSymbicort$1,433$9,40835 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$16$4,43413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other allergy in Tulsa

Where these figures come from

Is this you, or does something look wrong? →